a 2022

Novel endolysin of S. sciuri phage S10 and its antimicrobial effect on S. aureus

BENEŠÍK, Martin, Tomáš BARTEJS, Dominik CHMELÍK, Dana ŠTVERÁKOVÁ, Tibor BOTKA et. al.

Základní údaje

Originální název

Novel endolysin of S. sciuri phage S10 and its antimicrobial effect on S. aureus

Autoři

BENEŠÍK, Martin (203 Česká republika, domácí), Tomáš BARTEJS (203 Česká republika), Dominik CHMELÍK (203 Česká republika), Dana ŠTVERÁKOVÁ (203 Česká republika), Tibor BOTKA (203 Česká republika, garant, domácí), Marta ŠIBOROVÁ (203 Česká republika), Vítězslav FUGLÍK, Martina PARISOVÁ a Marek MOŠA

Vydání

Viruses of Microbes 2022, Guimarães, Portugal, 2022, 2022

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

10600 1.6 Biological sciences

Stát vydavatele

Portugalsko

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14310/22:00129692

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

phage therapy; lytic enzyme; Staphylococcus sciuri

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 4. 11. 2022 15:07, Mgr. Tibor Botka, Ph.D.

Anotace

V originále

A lot of novel bacteriophages were isolated, characterised and added to the microbial collection of Fagofarma (and MB Pharma) recently. Some of these phages are unique and their genomes encode potentially novel peptidoglycan hydrolases. Such as the phage S. sciuri S10, which was isolated from wastewater and its genome showed low similarity to sequences found in public databases. In its genome, two genes encoding hypothetical endolysin (LysS10) or tail peptidoglycan hydrolase (TPH) were identified. In this study, we focused on examination of potential activity of these two enzymes. Both genes were cloned, the proteins were expressed in E. coli and purified using chromatography. Zymogram was used as the first method for determination of activity on bacterial cell walls isolated from S. sciuri and S. aureus. This test proved activity of endolysin LysS10 on both types of cell walls. Activity of TPH was not proven, therefore, we focused mainly on LysS10 which activity was verified using spot assay and turbidity reduction assay. Moreover, LysS10 activity was compared with the LysK and the LysF1 on different strains and species of Staphylococcus, including MRSA. LysS10 had antimicrobial effect on every tested bacterium, but it was less active compared to LysK and LysF1. Antimicrobial effect of novel endolysin LysS10 was proven by different methods on several S. aureus strains and other staphylococcal species. Although the enzyme is not as efficient as LysK, there is potential for improving its properties by changing domains, protein design of the catalytic domain or increasing the solubility of the protein.

Návaznosti

NU21J-05-00035, projekt VaV
Název: Synergie lytických bakteriofágů a antibiotik v léčbě povrchových infekcí způsobených Staphylococcus aureus (Akronym: PAS-based therapy of S. aureus infections)
Investor: Ministerstvo zdravotnictví ČR, Synergy of lytic bacteriophages and antibiotics in the therapy of topical infections of Staphylococcus aureus, Podprogram 2 - juniorský - výzkumníci do 35 let